Skip to content
Screener

Cytokinetics CYTK Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.9×-0.9×
Eli Lilly logo
Eli LillyLLY
1.6×-0.6×
Merck & Co. logo
Merck & Co.MRK
1.1×+0.3×
Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
0.3×-0.1×
Edgewise Therapeutics, Inc. logo
Edgewise Therapeutics, Inc.EWTX
0×0.0×
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
0.1×0.0×

Other financials

Income statement

See full
Revenue$28.6M-57.1%
Operating income-$179.2M-60.7%
Net income-$198.8M-47.9%
EPS (diluted)-$1.50-33.9%

Balance sheet

See full
Cash & equivalents$255.3M+241%
Total debt$399.0M+31.2%
Total equity-$173.5M+52.9%
Total assets$1.9B+57.0%

Cash flow

See full
Operating cash flow-$159.8M-24.6%
CapEx$4.3M+4.6%
Free cash flow-$164.2M-24.0%

Valuation

See full
Market cap$10.71B+155%
Enterprise value$10.85B+145%
P/S158.2×+109×

Profitability

See full
Operating margin-1,046.1%+1,858pp
Net margin-1,321.1%+8,702pp
FCF margin-858.2%+1,799pp

Returns & leverage

See full
Return on equity-337.6%—
Current ratio6.7×-0.1×

Where this comes from

Calculated from Cytokinetics’s reported figures.

total debt/total stockholders equity=2.2×

Based on the most recent quarter.

The source filing: Cytokinetics’s 10-Q, filed August 9, 2024. Open the filing →

Filed
Aug 9, 2024
Fiscal quarter
Q2 FY2024
Calendar quarter
Q2 2024
Accession
0000950170-24-094743

FAQ

What is Cytokinetics's debt-to-equity?
Cytokinetics (CYTK) reported debt-to-equity of 2.2× in Q2 2024.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Cytokinetics's debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude